Despite increasing label indications across numerous cancer histologies, antibodies that block CTLA-4, PD-1, and PD-L1 are essentially ineffective in patients with advanced metastatic PDAC, linked mechanistically to a number of tumor-intrinsic and –extrinsic factors in the TME (Table 1) (3). This evidence concerns the gene CTLA4 and neoplasm.